NIPT Prenatal Screening Patents

Non-invasive prenatal testing (NIPT) patents cover cell-free-fetal-DNA detection innovations; sequencing/counting-method innovations; SNP-based and fetal-fraction innovations; and expanded-condition, bioinformatics, and assay innovations — with IP held by NIPT/genomics companies (in a field screening for fetal genetic abnormalities by analyzing fetal DNA circulating in the mother's blood, avoiding invasive amniocentesis). WHY NIPT: cell-free FETAL DNA (cffDNA, shed mostly by the placenta) circulates in maternal blood from early pregnancy; analyzing it lets clinicians SCREEN for fetal chromosomal abnormalities (Down syndrome/trisomy 21, trisomy 18/13, sex-chromosome aneuploidies, and microdeletions) from a simple maternal blood draw — far safer than amniocentesis/CVS (which carry miscarriage risk) and earlier/more accurate than older serum screens. MAJOR NIPT PATENT HOLDERS: SEQUENOM: foundational cell-free fetal DNA NIPT (MaterniT21) — central to the landmark Ariosa v. Sequenom §101 case. NATERA: Panorama — SNP-based NIPT (distinguishing fetal vs maternal alleles). ILLUMINA (acquired Verinata): massively-parallel sequencing/counting NIPT. ROCHE/ARIOSA (Harmony), LABCORP/INTEGRATED GENETICS, BGI, and academic licensors (Lo et al., the cffDNA discovery). cffDNA detection, sequencing/counting methods, SNP/fetal-fraction methods, and expanded conditions/bioinformatics are the core NIPT patent domains — and SNP-based methods, low-fetal-fraction handling, single-gene NIPT, and §101-eligible claims are the open whitespace.

Patent-eligibility (§101) is THE defining legal issue for NIPT and diagnostic patents — and Ariosa v. Sequenom is the landmark precedent every NIPT founder must understand. THE ARIOSA v. SEQUENOM DECISION: Sequenom held a patent on a method of detecting paternally-inherited cell-free fetal DNA in maternal plasma/serum (a genuinely revolutionary discovery that founded the NIPT field). The Federal Circuit nonetheless held the claims patent-INELIGIBLE under 35 U.S.C. §101 — reasoning that the EXISTENCE of cffDNA in maternal blood is a NATURAL PHENOMENON, and the claimed steps (amplifying and detecting it) used CONVENTIONAL, routine techniques, so the claim merely applied routine methods to a natural phenomenon (failing the Mayo/Alice two-step test). The Supreme Court declined to hear the appeal, leaving it as binding precedent. WHY IT MATTERS: it is the canonical example that even a brilliant, non-obvious DISCOVERY of a natural correlation/phenomenon can be patent-ineligible if the claim just detects it with conventional methods — a major problem for diagnostic-method patents generally (alongside Mayo v. Prometheus). IMPLICATIONS FOR NIPT IP: claims that recite 'detect natural cffDNA using known sequencing' are vulnerable; founders must instead claim NOVEL, non-routine TECHNIQUES — specific improved sample-prep, novel sequencing/library methods, specific algorithmic/bioinformatic processing, SNP-based analytical methods, or new assay compositions/apparatus — that add an 'inventive concept' beyond the natural phenomenon. The §101 patent-eligibility analysis (natural phenomenon + conventional steps = ineligible) is the single most important consideration in NIPT patent strategy, making HOW you detect (novel technique) far more defensible than the discovery THAT cffDNA exists.

Sequencing/counting-method innovations; SNP-based and allele-analysis innovations; fetal-fraction and low-input innovations; and expanded-condition, bioinformatics, and assay innovations represent core NIPT patent domains — and because the underlying biology (cffDNA exists) isn't patentable, the patentable value is in the specific, non-routine METHODS, algorithms, and assays. SEQUENCING / COUNTING-METHOD PATENTS: massively-parallel sequencing approaches that COUNT chromosome representation (an over-representation of chromosome 21 sequences indicates trisomy 21) — specific library prep, sequencing protocols, normalization, and counting/statistical methods (Sequenom/Illumina); the specific improved technique (not generic sequencing) is key for both performance and §101. SNP-BASED / ALLELE-ANALYSIS PATENTS: analyzing single-nucleotide polymorphisms to DISTINGUISH fetal from maternal alleles and infer fetal copy number (Natera Panorama) — targeted SNP panels, allele-ratio analysis, and parental-genotype modeling; a distinct, defensible analytical approach. FETAL-FRACTION / LOW-INPUT PATENTS: measuring and handling the FETAL FRACTION (the proportion of cffDNA that is fetal — low fetal fraction causes failed/false results), enriching fetal DNA, size-selection, and reliable calling at low input. EXPANDED-CONDITION / BIOINFORMATICS / ASSAY PATENTS: extending NIPT to microdeletions, SINGLE-GENE disorders, fetal RhD, fetal whole-genome, and twin/IVF pregnancies; bioinformatic/algorithmic processing and ML calling; and assay/kit compositions and apparatus. Specific novel sequencing/library techniques, SNP-based analytical methods, fetal-fraction handling, and bioinformatic algorithms are the highest-value NIPT IP because they both improve performance AND provide the inventive, non-routine concept needed for §101 eligibility.

NIPT startup IP strategy must navigate Sequenom/Natera/Illumina portfolios, dense NIPT prior art and extensive past LITIGATION (the NIPT field saw major patent wars among Sequenom, Verinata/Illumina, Natera, Ariosa — eventually broad cross-licensing), the §101 patent-eligibility problem (Ariosa v. Sequenom — the central constraint), the sensitivity/specificity and fetal-fraction challenges, the regulatory/clinical-validation (LDT/FDA) realities, the cost/reimbursement constraints, and a landscape where specific methods, SNP analysis, fetal-fraction handling, bioinformatics, and assays are the durable assets; understand that the cffDNA discovery is unpatentable (natural phenomenon) and basic counting NIPT is heavily patented/litigated, so the durable IP is in NOVEL non-routine techniques, SNP-based methods, fetal-fraction/low-input handling, expanded single-gene conditions, and bioinformatic algorithms, and that §101 eligibility, accuracy, validation, and reimbursement matter as much as patents; identify whitespace in single-gene NIPT, SNP methods, and algorithms. NIPT STARTUP IP STRATEGY: §101 IS THE CENTRAL CONSTRAINT — CLAIM NOVEL TECHNIQUES, NOT THE NATURAL PHENOMENON: per Ariosa v. Sequenom, detecting natural cffDNA with conventional methods is ineligible — claim specific novel sample-prep/sequencing/SNP/algorithmic/assay techniques with an inventive concept beyond the natural phenomenon; THE cffDNA DISCOVERY ITSELF IS UNPATENTABLE — METHODS AND ASSAYS ARE THE IP: build IP around HOW you detect (specific improved methods, SNP analysis, bioinformatics, kits/apparatus), not THAT cffDNA exists; SNP-BASED ANALYSIS IS A DISTINCT, DEFENSIBLE APPROACH: parental-genotype/allele-ratio methods (Natera) differ from counting and offer differentiated, more §101-defensible analytical IP; FETAL-FRACTION HANDLING AND ACCURACY ARE HIGH-VALUE: reliable calling at low fetal fraction (a key failure mode) and improved sensitivity/specificity (false positives require costly confirmatory testing) are valuable and patentable; EXPANDED CONDITIONS (SINGLE-GENE NIPT) ARE WHITESPACE: moving beyond aneuploidy to single-gene disorders, microdeletions, RhD, and broader genomes opens newer, less-crowded IP; BEWARE THE LITIGIOUS LANDSCAPE AND FTO: NIPT has heavy patent litigation/cross-licensing history — FTO and licensing strategy are as important as filing; VALIDATION AND REIMBURSEMENT GATE THE BUSINESS: clinical validation (sensitivity/specificity/PPV), regulatory (LDT/FDA), and payer reimbursement determine viability — data matters more than patents alone; WHEN TO PATENT: NOVEL METHOD/ALGORITHM/ASSAY WITH MEASURED PERFORMANCE AND §101 IN MIND: file once a method shows measured results (sensitivity/specificity/PPV per condition + fetal-fraction performance + condition breadth + cost/turnaround) AND can be claimed as a novel non-routine technique — measured accuracy/PPV and §101-eligible technical novelty are the critical NIPT IP metrics; KEY FTO CHECKLIST: Sequenom cffDNA/MaterniT21 (Ariosa §101 precedent — ineligibility risk); Natera Panorama SNP-based; Illumina/Verinata counting/massively-parallel-sequencing; Roche/Ariosa Harmony; cffDNA detection (natural phenomenon — §101); counting/chromosome-representation; SNP allele-ratio/parental-genotype; fetal-fraction estimation/enrichment/size-selection; microdeletion/single-gene/RhD/whole-genome expansion; bioinformatic/ML calling algorithms; assay/kit/apparatus composition; NIPT litigation/cross-licensing history; §101 Mayo/Alice diagnostic-eligibility.